In vivo knockdown of nicotinic acetylcholine receptor α1 diminishes aortic atherosclerosis

Atherosclerosis

Volumn 215, Issue 1, 2011, Pages 34-42

  Zhang, Guoqiang ^a   Marshall, Amanda L ^a   Thomas, Alison L ^a   Kernan, Kelly A ^a   Su, Yanyuan ^a   LeBoeuf, Renee C ^a   Dong, Xiu Rong ^a   Tchao, B N Angela ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Atherosclerosis; Gene knockdown; Interferon ; Nicotinic acetylcholine receptor 1; Transforming growth factor ; Y box protein 1

Indexed keywords

APOLIPOPROTEIN E; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA1; PLASMID DNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE SILENCING; GENE TRANSFER; GENETIC CODE; IN VIVO STUDY; MACROPHAGE; MOUSE; MYOFIBROBLAST; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; UPREGULATION;

ACTINS; ANIMALS; AORTA; AORTIC DISEASES; ATHEROSCLEROSIS; FEMALE; GENE SILENCING; INTERFERON-GAMMA; MACROPHAGES; MICE; MYOFIBROBLASTS; RECEPTORS, NICOTINIC; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 79952106040     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.07.057     Document Type: Article

References (30)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med 2005, 352:1685-1695.
2. Poirier P., Giles T.D., Bray G.A., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation 2006, 113:898-918.
3. Assmann A., Mohlig M., Osterhoff M., Pfeiffer A.F.H., Spranger J. Fatty acids differentially modify the expression of urokinase type plasminogen activator receptor in monocytes. Biochem Bioph Res Commun 2008, 376:196-199.
4. Andersson J., Libby P., Hannson G.K. Adaptive immunity and atherosclerosis. Clin Immunol 2010, 134:33-46.
5. Cooke J.P. Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor. Life Sci 2007, 80:2347-2351.
6. Heeschen C., Jang J.J., Weis M., et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001, 7:833-839.
7. Kanda Y., Watanabe Y. Nicotine-induced vascular endothelial growth factor release via the EGFR-ERK pathway in rat vascular smooth muscle cells. Life Sci 2007, 80:1409-1414.
8. Zhang G., Kernan K.A., Thomas A., et al. A novel signaling pathway: fibroblast nicotinic receptor α1 binds urokinase and promotes renal fibrosis. J Biol Chem 2009, 284:29050-29064.
9. Carlisle D.L., Liu X., Hopkins T.M., et al. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm Pharmacol Ther 2007, 20:629-641.
10. Cooke J.P., Ghebremariam Y.T. Endothelial nicotinic acetylcholine receptors and angiogenesis. Trends Cardiovasc Med 2008, 18:247-253.
11. Rychahou P.G., Evers B.M. Hydrodynamic delivery protocols. Methods Mol Biol 2010, 623:189-195.
12. Zhang G., Kim H., Xiaohe C., et al. Urokinase receptor modulates cellular and angiogenic responses in obstructive nephropathy. J Am Soc Nephrol 2003, 14:1234-1253.
13. Zhang G., Kim H., Xiaohe C., et al. Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol 2003, 14:1254-1271.
14. Zhang G., Kernan K.A., Collins S.J., et al. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol 2007, 18:846-859.
15. Vetrone S.A., Montecino-Rodriguez E., Kudryashova E., et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-β. J Clin Invest 2009, 119:1583-1594.
16. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994, 14:133-140.
17. Chiba S., Pkamoto H., Kon S., et al. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels 2002, 16:111-117.
18. Desmouliere A., Geinoz A., Gabbiani F., Gabbiani G. Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultures fibroblasts. J Cell Biol 1993, 122:103-111.
19. Dooley S., Said H.M., Gressner A.M., et al. Y-box protein-1 is the crucial mediator of antifibrotic interferon-γ effects. J Biol Chem 2006, 281:1784-1795.
20. Linton M.F., Atkinson J.B., Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995, 267:1034-1037.
21. Takahashi F., Akutagawa S., Fukumoto H., et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer 2002, 98:707-712.
22. Bobik A., Agrotic A., Kanellakis P., et al. Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. Circulation 1999, 99:2883-2891.
23. Lutgens E., Daemen M.J. Transforming growth factor-beta: a local or systemic mediator of plaque stability. Circ Res 2001, 89:853-855.
24. Mallet Z., Gojova A., Marchiol-Fournigault C., et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induced an unstable plaque phenotype in mice. Circ Res 2001, 89:930-934.
25. Otsuka G., Agah R., Frutkin A.D., Wight T.N., Dichek D.A. Transforming growth factor beta-1 induced neointima formation through plasminogen activator inhibitor-1-dependent pathways. Arterioscler Thromb Vasc Biol 2006, 26:737-743.
26. McLaren J.E., Ramji D.P. Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev 2009, 20:125-135.
27. Niwa T., Wada H., Ohashi H., et al. Interferon-gamma produced by bone marrow-derived cells attenuates atherosclerotic lesion formation in LDLR-deficient mice. J Atheroscler Thromb 2004, 11:79-87.
28. Hansson G.K., Hellstraand M., Rymo L., Rubbia L., Gabbiani G. Interferon-γ inhibits smooth muscle cell proliferation and expression of differentiation-specific α-smooth muscle actin in arterial smooth muscle cells. J Exp Med 1989, 170:1595-1608.
29. Liu J., Shue E., Ewalt K.L., Schimmel P. A new gamma-interferon-inducible promoter and splice variants of an anti-angiogenic human tRNA synthetase. Nucleic Acids Res 2004, 32:719-727.
30. Wakasugi K., Slike B.M., Hood J., et al. A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc Natl Acad Sci USA 2002, 99:173-177.